Modern science offers a novel strategy to target the most challenging infections fueled by biofilms. Learn more about our important work to combat these infections and reduce antibiotic resistance.Our Science An innovative, strategically focused management team with deep anti-infective therapeutic and vaccine development expertise.Meet The Team In the News Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator FundJanuary 28, 2025 Clarametyx Biosciences Awarded a Multi-Phased Agreement with CARB-X to Accelerate Anti-Biofilm Vaccine to Prevent Bacterial InfectionsJanuary 7, 2025 Clarametyx Bioscience Recognized as “Infectious Disease Innovation of the Year” In 2024 BioTech Breakthrough AwardsNovember 19, 2024 Clarametyx Biosciences Announces Progress on Study of Antibody Therapy CMTX-101 For Infections Associated With Cystic FibrosisOctober 17, 2024